The $600 Million Pet CBD Boom: Why Your Dog's Vet Can Finally Talk About Cannabis in 2026

For years, pet owners who gave their arthritic golden retriever CBD oil or their anxious rescue cat a hemp-infused treat were navigating a strange gray zone. They could buy the products at dispensaries, pet stores, and online retailers. They could read glowing testimonials from other pet owners. But the one person they most needed guidance from — their veterinarian — often couldn't say a word about it without risking their license. That era is finally ending, and the pet CBD market is exploding as a result.

The global pet CBD market is estimated at approximately $600 million in 2026, with projections showing growth to $5.5 billion by 2034 at a compound annual growth rate of 32.5 percent. Those aren't typos. The pet CBD sector is growing faster than nearly any other segment in the cannabis industry, driven by a convergence of regulatory breakthroughs, veterinary science, and the simple fact that Americans will spend almost anything to help their pets feel better.

Maryland Breaks New Ground

The most significant development of 2026 arrived in April when Maryland Governor Wes Moore signed a pair of bills — Senate Bill 54 from Senator Clarence Lam and House Bill 452 from Delegate Michele Guyton — that explicitly protect veterinarians who discuss or recommend cannabis and CBD products for animals.

The legislation is straightforward in its impact: the State Board of Veterinary Medical Examiners can no longer suspend, revoke, or restrict a veterinarian's license solely because they discussed or recommended cannabis or cannabidiol products for an animal's potential therapeutic benefit. Both bills passed their respective chambers unanimously, reflecting broad bipartisan recognition that the previous regulatory framework was failing both veterinarians and the animals in their care.

Maryland's new law, which takes effect October 1, makes it the fifth state to enact specific veterinary cannabis protections, joining California, Nevada, Michigan, and Utah. But the significance extends beyond state borders. Each state that passes such legislation creates a template for others and further normalizes the conversation between pet owners and the medical professionals they trust most.

Why Veterinarians Were Silent

To understand why this matters, you need to understand the bind that veterinarians have been in. Unlike human medicine, where doctors can discuss and even recommend cannabis in states with legal programs, veterinary medicine has operated under a chilling effect. State veterinary boards could — and in some cases did — investigate or discipline vets who discussed cannabis with clients, viewing it as recommending an unapproved substance.

This created an absurd situation. Pet owners were buying CBD products for their animals in record numbers, often based on internet research and anecdotal reports. Meanwhile, the professionals with the training and expertise to guide those decisions were effectively gagged. A veterinarian might know that a particular dose of CBD could help manage a dog's arthritis without the side effects of traditional NSAIDs, but recommending it could trigger a board investigation.

The result was exactly what you'd expect: pet owners making dosing decisions without professional guidance, purchasing products of varying quality from unregulated sources, and sometimes giving their animals products that were either ineffective or inappropriate for their specific conditions. Veterinarians, for their part, were left to either break the rules quietly, offer cryptic non-recommendations, or simply change the subject.

The Market Responds

The numbers tell a story of pent-up demand finally finding an outlet. A 2024 study by the American Pet Products Association found that 59 percent of dog owners and 52 percent of cat owners were open to using CBD products for their pets. That willingness has translated into real spending as more consumers gain confidence in the products and access to professional guidance.

The pet CBD market breaks down along several product lines. Oils and tinctures remain the most popular format, valued for their dosing precision and ease of administration. Treats and chews are the fastest-growing segment, offering convenience and palatability that makes daily dosing less of a battle. Topical products, including balms and sprays for skin conditions and localized pain, represent a smaller but growing category.

Within these categories, joint health and pain management products are driving the most revenue. Osteoarthritis is a growing concern in dogs, particularly among larger breeds, and CBD's anti-inflammatory properties have made it an attractive complementary treatment. Stress and anxiety relief is the second-largest use case, with CBD products helping pets manage separation anxiety, noise phobias (thunderstorms, fireworks), and general nervousness.

Interestingly, the cat product market appears poised for the most growth relative to its current size. Cat owners have been slower to adopt CBD products than dog owners, but awareness is increasing rapidly. CBD products targeted at feline joint health and arthritis pain relief are seeing particularly strong uptake as veterinarians become more willing to discuss these options.

What the Science Actually Shows

The growing market has outpaced the science in some respects, but research is catching up. Several studies have demonstrated CBD's efficacy for specific conditions in animals, with results that veterinary professionals find encouraging even if more research is needed.

The most robust evidence exists for pain management. A 2018 study published in Frontiers in Veterinary Science found that CBD oil significantly decreased pain and increased activity in dogs with osteoarthritis, with no observable side effects at the doses studied. Subsequent research has largely confirmed these findings, establishing a reasonably strong evidence base for CBD as a complementary treatment for canine joint pain.

Anxiety management has a thinner but growing evidence base. Studies have shown that CBD can reduce cortisol levels and behavioral indicators of stress in dogs, though optimal dosing varies significantly by weight, breed, and individual sensitivity. This is precisely the kind of nuance that requires veterinary guidance — one-size-fits-all dosing recommendations from product labels are rarely adequate.

Seizure management is an area of active research with promising early results. The FDA's approval of Epidiolex for human epilepsy has spurred interest in CBD's anticonvulsant properties for animals, and several veterinary clinical trials are underway.

What the science consistently emphasizes, however, is the importance of product quality. The pet CBD market, like the broader CBD market, is plagued by products that don't contain what they claim. Studies have found significant discrepancies between labeled and actual CBD content in pet products, and some products have contained detectable levels of THC — which is toxic to dogs at sufficient doses. This quality control issue is a primary reason why veterinary guidance is so important.

The Quality Question

The absence of FDA regulation for most CBD pet products means that quality varies enormously. Premium brands invest in third-party lab testing, use organic hemp, and publish certificates of analysis that verify cannabinoid content and the absence of contaminants like heavy metals, pesticides, and residual solvents.

But for every reputable brand, there are others cutting corners. A lack of standardization means that a "25mg CBD dog treat" from one company may deliver a very different experience than the same labeled dose from another. Extraction methods, carrier oils, and bioavailability all affect how much CBD actually reaches the animal's system.

The veterinary community's increased ability to discuss these products with clients may be the most powerful quality control mechanism available. A veterinarian can recommend specific brands they trust, advise on appropriate dosing based on the animal's weight and condition, and monitor for interactions with other medications. This kind of professional oversight has been largely missing from the pet CBD market, and its emergence could help separate legitimate products from snake oil.

Product Innovation in 2026

The pet CBD market in 2026 is characterized by increasingly sophisticated products. Nano-emulsion technology, which breaks CBD molecules into smaller particles for faster absorption, has moved from human products into the pet market. These nano-CBD formulations offer onset times of 15 to 20 minutes compared to 45 to 90 minutes for traditional oil-based products.

Functional blends are another trend, with products combining CBD with other supplements like glucosamine, chondroitin, and turmeric for comprehensive joint health support. These multi-ingredient formulations appeal to pet owners who want to simplify their animal's supplement regimen.

Species-specific formulations are also gaining traction. Because cats metabolize cannabinoids differently than dogs, products specifically designed for feline physiology — with adjusted CBD concentrations and cat-friendly carrier oils — are becoming more common and more refined.

The Business Opportunity

For entrepreneurs and investors, the pet CBD space remains one of the most attractive segments in the broader cannabis industry. The combination of rapid growth, relatively low regulatory barriers (compared to THC products), and an enormous addressable market — Americans spent $150 billion on their pets in 2024 — creates a compelling opportunity.

The market is also benefiting from distribution advantages that THC products don't enjoy. Pet CBD products can be sold online, in pet stores, and in mainstream retail outlets, bypassing the dispensary-only limitation that constrains THC product distribution. This broader retail presence, combined with the destigmatizing effect of veterinary endorsement, positions pet CBD for continued rapid growth.

Premium positioning is key to the business model. The pet owners most likely to purchase CBD products tend to be those who already spend above average on pet care — a demographic that's less price-sensitive and more quality-conscious. Brands that can demonstrate veterinary backing, clinical evidence, and rigorous quality testing command significant price premiums over generic competitors.

Looking Ahead

The trajectory of the pet CBD market points toward continued rapid growth as more states follow Maryland's lead in protecting veterinary discussions, as research builds a stronger evidence base, and as product quality standards improve.

The biggest remaining challenge is federal regulatory clarity. The FDA has not yet established a clear framework for CBD in animal products, creating uncertainty that makes some mainstream retailers and veterinary practices cautious about full engagement. A clear FDA pathway — whether through formal approval or enforcement discretion guidelines — would likely accelerate market growth significantly.

For now, the trend is unmistakable. Pet owners want CBD products for their animals. Veterinarians want to guide those decisions responsibly. And a $600 million market is growing at 32 percent annually because the demand is real, the science is promising, and the regulatory walls that kept veterinarians from having honest conversations about cannabis are finally coming down.

Your dog's vet can talk about CBD now. And that might be the most important development in pet health this year.